Verified Clinical Trials and WindRose Health Investors Form Strategic Partnership to Enhance Growth
In a significant advancement for clinical research, Verified Clinical Trials (VCT), a leading provider of clinical trial subject registry solutions, has announced a strategic partnership with WindRose Health Investors. This collaboration signals the beginning of an exciting new chapter aimed at propelling VCT’s growth and enhancing its capabilities within the healthcare sector.
VCT is well-known for its industry-recognized platform that emphasizes patient safety, data integrity, and compliance throughout the entirety of clinical studies. The firm specializes in identifying and preventing duplicate enrollments, along with addressing critical protocol violations that could jeopardize the safety of research subjects and the quality of data collected. This partnership with WindRose is not just about financial investment; it represents an alignment of shared goals to further enhance the clinical trial landscape.
The partnership’s inception is a culmination of VCT's rapid growth and recognition in providing invaluable registry solutions to sponsors, Contract Research Organizations (CROs), and research sites. The investment from WindRose underscores the immense value that VCT creates by fortifying the integrity of clinical research data. This investment is expected to reduce avoidable risks while bolstering safety protocols essential for successful clinical trials. With additional capital at its disposal, VCT plans to enhance its infrastructure, expand its service offerings, and broaden its geographical footprint.
To lead this next phase of growth, Howard Miller has been appointed as the Chief Executive Officer of VCT. Bringing over three decades of experience in healthcare and life sciences, Miller has a demonstrated track record within various leadership roles such as the CEO of Envision Pharma Group and COO of Two Labs. His extensive experience at high-profile firms like Abbott and Novavax equips him with the insights necessary to guide VCT into its next era.
Co-founders Mitchell Efros, MD, and Kerri Weingard, ANP, will continue to play integral roles as the landscape of VCT evolves. Efros will serve as President and work on enhancing client relationships, while Weingard takes on the role of Chief of Strategic Operations, focusing on continual improvements to VCT’s operational effectiveness. Their hands-on engagement ensures that the company's long-standing commitment to client partnerships and research integrity remains steadfast.
In a shared statement, Efros and Weingard expressed their enthusiasm for the partnership, emphasizing that it was the perfect moment to align with WindRose and Miller, who both have extensive experience in scaling pharmaceutical services. This dynamic collaboration allows VCT to focus on broadening its client relationships and executing strategic investments, thereby setting a new benchmark for safety and transparency within clinical research.
Miller has expressed his eagerness to join VCT, reiterating the value of the proprietary subject registry technology and his belief that its broader application can expedite the delivery of safe innovative treatments to patients in need. Maintaining an eye on the evolving clinical landscape, he aims to leverage VCT's strengths to ensure that all stakeholders, including sponsors and CROs, see the tangible benefits of working with VCT's unique solutions.
CJ Burnes, a Partner at WindRose, shared the firm’s confidence in VCT’s potential, highlighting their eagerness to collaborate closely with Miller, Efros, and Weingard. He pointed out that VCT has cultivated a novel solution that minimizes risk for all participants in the clinical research ecosystem—improving safety, data integrity, and overall trial efficiency.
As VCT embarks on this new journey, it reaffirms its commitment to upholding the highest standards of patient safety, regulatory compliance, and data quality. This strategic partnership with WindRose is anticipated to pave the way for groundbreaking advancements in clinical trials, ultimately enhancing the healthcare landscape and improving patient outcomes.
VCT is well-known for its industry-recognized platform that emphasizes patient safety, data integrity, and compliance throughout the entirety of clinical studies. The firm specializes in identifying and preventing duplicate enrollments, along with addressing critical protocol violations that could jeopardize the safety of research subjects and the quality of data collected. This partnership with WindRose is not just about financial investment; it represents an alignment of shared goals to further enhance the clinical trial landscape.
The partnership’s inception is a culmination of VCT's rapid growth and recognition in providing invaluable registry solutions to sponsors, Contract Research Organizations (CROs), and research sites. The investment from WindRose underscores the immense value that VCT creates by fortifying the integrity of clinical research data. This investment is expected to reduce avoidable risks while bolstering safety protocols essential for successful clinical trials. With additional capital at its disposal, VCT plans to enhance its infrastructure, expand its service offerings, and broaden its geographical footprint.
To lead this next phase of growth, Howard Miller has been appointed as the Chief Executive Officer of VCT. Bringing over three decades of experience in healthcare and life sciences, Miller has a demonstrated track record within various leadership roles such as the CEO of Envision Pharma Group and COO of Two Labs. His extensive experience at high-profile firms like Abbott and Novavax equips him with the insights necessary to guide VCT into its next era.
Co-founders Mitchell Efros, MD, and Kerri Weingard, ANP, will continue to play integral roles as the landscape of VCT evolves. Efros will serve as President and work on enhancing client relationships, while Weingard takes on the role of Chief of Strategic Operations, focusing on continual improvements to VCT’s operational effectiveness. Their hands-on engagement ensures that the company's long-standing commitment to client partnerships and research integrity remains steadfast.
In a shared statement, Efros and Weingard expressed their enthusiasm for the partnership, emphasizing that it was the perfect moment to align with WindRose and Miller, who both have extensive experience in scaling pharmaceutical services. This dynamic collaboration allows VCT to focus on broadening its client relationships and executing strategic investments, thereby setting a new benchmark for safety and transparency within clinical research.
Miller has expressed his eagerness to join VCT, reiterating the value of the proprietary subject registry technology and his belief that its broader application can expedite the delivery of safe innovative treatments to patients in need. Maintaining an eye on the evolving clinical landscape, he aims to leverage VCT's strengths to ensure that all stakeholders, including sponsors and CROs, see the tangible benefits of working with VCT's unique solutions.
CJ Burnes, a Partner at WindRose, shared the firm’s confidence in VCT’s potential, highlighting their eagerness to collaborate closely with Miller, Efros, and Weingard. He pointed out that VCT has cultivated a novel solution that minimizes risk for all participants in the clinical research ecosystem—improving safety, data integrity, and overall trial efficiency.
As VCT embarks on this new journey, it reaffirms its commitment to upholding the highest standards of patient safety, regulatory compliance, and data quality. This strategic partnership with WindRose is anticipated to pave the way for groundbreaking advancements in clinical trials, ultimately enhancing the healthcare landscape and improving patient outcomes.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.